A Phase 4 interventional study of Tetanus Immune Globulin (Human) and Diphtheria-Tetanus Toxoids Adsorbed in Tetanus, sponsored by Grifols Therapeutics LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-20.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 4, Interventional, and Prevention
The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with strict control on the anatomical location and timing of administration of TIG and TT. Pharmacokinetic profile of antibody titer including the duration of adequate titer protection provided by TIG and TT given in combination will be assessed using a standardized administration regimen and standardized antibody assay procedure. This study may provide evidence for the recommendations of the World Health Organisation (WHO) whereby dual coverage with both a vaccine and tetanus hyperimmune would ideally provide the best coverage for anyone with the potential of developing tetanus.
This is a prospective, open-label, single-center trial including a single group of subjects with no known primary immunization history with TT or >10 years have passed since the last dose of tetanus containing vaccine was received. The study will enroll six subjects who would receive both dT and TIG concurrently on Day 1.
All dosed subjects will be followed for 40 days during which Day 1, 2, 3, 4, 5, 7, 14, 21, 30 and 40 time levels of tetanus antibodies will be measured in order to determine the serum level vs. time curve, Cmax, Tmax, and duration of protective antibody levels.
206 studies on the registry are indexed under Tetanus; 22 are open to participants now.
This study's enrollment of 6 is below the median of 400 across 178 interventional studies indexed under Tetanus.
Browse Tetanus studies →Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
First submitted before Grifols Therapeutics LLC became part of Grifols.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Tetanus Immune Globulin (Human) · Biological: Diphtheria-Tetanus Toxoids Adsorbed
Based on package insert recommendation and recommendations of WHO
Also known as: HyperTET S/D, BayTet, BAY 19-8515, TAL-05-00013, NDC 13533-634-02
Based on package insert recommendations and recommendations of WHO
Antibody titer serum level at each time point
Time frame: 40 days
Cmax
Time frame: 40 days
Tmax
Time frame: 40 days
The record gives a start of Mar 2007, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.